Advertisement
UK markets close in 8 hours 3 minutes
  • FTSE 100

    8,221.51
    -3.82 (-0.05%)
     
  • FTSE 250

    20,301.61
    +3.51 (+0.02%)
     
  • AIM

    764.04
    -1.88 (-0.25%)
     
  • GBP/EUR

    1.1821
    +0.0005 (+0.04%)
     
  • GBP/USD

    1.2643
    +0.0019 (+0.15%)
     
  • Bitcoin GBP

    48,018.46
    -778.08 (-1.59%)
     
  • CMC Crypto 200

    1,261.69
    -4.45 (-0.35%)
     
  • S&P 500

    5,477.90
    +8.60 (+0.16%)
     
  • DOW

    39,127.80
    +15.64 (+0.04%)
     
  • CRUDE OIL

    80.72
    -0.18 (-0.22%)
     
  • GOLD FUTURES

    2,311.70
    -1.50 (-0.06%)
     
  • NIKKEI 225

    39,341.54
    -325.53 (-0.82%)
     
  • HANG SENG

    17,713.73
    -376.20 (-2.08%)
     
  • DAX

    18,202.54
    +47.30 (+0.26%)
     
  • CAC 40

    7,620.07
    +10.92 (+0.14%)
     

Merck Prepares to Take on Pfizer After Pneumococcal Vaccine Approval

Merck Prepares to Take on Pfizer After Pneumococcal Vaccine Approval

Pfizer currently dominates the market for pneumococcal vaccines, which protect against bacterial infections that can cause pneumonia and meningitis, among other conditions. Merck, however, has been nipping at Pfizer’s heels for years. The company sells Vaxneuvance and Pneumovax 23, pneumococcal vaccines with combined 2023 revenue of $1.1 billion.